Drug intelligence / Profile preview

eluvixtamab

Development stage: Discontinued
Lead developer: Amgen
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Eluvixtamab is a recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv): one directed against the tumor-associated antigen CD33 and the other against the CD3 antigen on T lymphocytes. By simultaneously binding to CD33 on malignant cells and CD3 on T-cells, eluvixtamab redirects cytotoxic T lymphocytes to target and kill CD33-expressing cancer cells, primarily in acute myeloid leukemia (AML). The drug was developed by Amgen and BeiGene for immunostimulatory and antineoplastic purposes but its clinical development for AML has been discontinued[1][3][4].

Other names: eluvixtamab

Targets

CD3 (T-cell surface glycoprotein CD3)CD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on eluvixtamab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eluvixtamab.

Explore the full profile